Familial hyperlipidemia: Resolving a case using evidence-based medicine
Abstract
Background: familial hypercholesterolemia (FH) and familial hyperlipidemia combined (HFC) are metabolic disorders of lipids associated with increase of the risk for cerebrovascular disease. Clinical case: 8-years-old Indigenous child with HFC presented right hemiparesis, motor aphasia and right central facial paralysis for a cerebral ischemic accident; in addition, he had altered lipid profile and family history of hypercholesterolemia. Methodology: this article used patient`s therapeutic approach using evidence-based medicine (EBM), started from a structured clinical question and PubMED search. Four systematic reviews were included. Discussion: statins are safe in children with HF and HFC are effective in improving lipid profile. EBM methodology could help to solve similar therapeutic problems.Downloads
References
McGill HC, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, et al. Associations of Coronary Heart Disease Risk Factors With the Intermediate Lesion of Atherosclerosis in Youth. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20(8):1998 –2004.
Berenson G., Srinivasan S., Bao W, Wattigney W., Newman III W., Tracy R. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. New Engl. J. Med. 1998 jul 20;338(23):1650–6.
Kwiterovich PO. Clinical and laboratory assessment of cardiovascular risk in children: Guidelines for screening, evaluation, and treatment. Journal of Clinical Lipidology. 2008 ago;2:248–66.
Garg A, Simha V. Update on Dyslipidemia. Journal of Clinical Endocrinology & Metabolism. 2007 may 1;92(5):1581 –1589.
Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2010;(7):CD006401.
Kavey R-EW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation. 2003 mar 25;107(11):1562 –1566.
CEBM > EBM Tools > Asking Focused Questions [Internet]. http://www.cebm.net/?o=1036 [citado 2010 nov 25].
Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011; 214(1):129–38.
O’Gorman CS, Higgins MF, O’Neill MB. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol. 2009;30(4):482–9.
Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(8):1803 –1810.
Daniels SR, Greer FR, and the Committee on Nutrition. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics. 2008;122(1):198 –208.
Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon M-C, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272–80.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 oct 8 ;366(9493):1267–78.
.png)
